2023 World Conference on Lung Cancer (Posters)-EP03.06. The Landscape of NF1 Alteration in Chinese Non-Small-Cell Lung Cancer Patients

EP03.06. The Landscape of NF1 Alteration in Chinese Non-Small-Cell Lung Cancer Patients - PDF(Slides)

Pdf Summary

This study analyzed the landscape of NF1 alterations in Chinese non-small-cell lung cancer (NSCLC) patients. The NF1 gene, which encodes the neurofibromin protein and regulates Ras signaling, was found to be altered in 5.1% of NSCLC samples in the study cohort. The study also compared the prevalence of NF1 mutations in different groups of patients and found that the EGFR mutation rate was lower in patients with NF1 mutations compared to those without NF1 mutations.<br /><br />The study used hybridization capture-based next-generation sequencing to identify alterations in 1331 normal-paired samples from lung cancer patients. The alterations identified included single base substitutions, insertions/deletions, copy number variations, gene fusions, and rearrangements.<br /><br />The study found that NF1 mutation carriers had other actionable or driver mutations, with TP53 being the most frequent (67.6%), followed by EGFR (32.4%), LRP1B (27.9%), PTPRD (20.6%), and CDKN2A (20.6%). NF1/EGFR co-mutation patients had longer overall survival compared to patients with a single mutation of NF1 or EGFR.<br /><br />The study also analyzed the age and gender distribution of NF1-mutated patients and found that they were more likely to be elderly and male. Furthermore, TP53 mutation was enriched in NF1 mutant patients.<br /><br />Overall, the study suggests that NF1 genetic alterations occur in a subset of NSCLC patients and that NF1 aberrations are important for identifying prognosis and therapeutic target candidates.

Asset Subtitle

Zhenliang Shi

Meta Tag

Speaker Zhenliang Shi

Topic Tumor Biology: Translational Biology - Translational Therapeutics

Keywords

NF1 alterations

Chinese non-small-cell lung cancer

NSCLC patients

neurofibromin protein

Ras signaling

EGFR mutation

hybridization capture-based next-generation sequencing

driver mutations

TP53 mutation

prognosis and therapeutic targets